STAT3 inhibition by microtubule-targeted drugs: Dual molecular effects of chemotherapeutic agents

Molecular and Cellular Pharmacology

Volumn 3, Issue 1, 2011, Pages 13-19

  Walker, Sarah R ^a   Chaudhury, Mousumi ^a   Frank, David A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer; Chemotherapy; Phosphorylation; Signal transduction; Targeted therapy; Transcription factors

Indexed keywords

AZACITIDINE; NAVELBINE; NIFUROXAZIDE; PACLITAXEL; STAT3 PROTEIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CYTOTOXICITY; DNA METHYLATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME ACTIVATION; GENE EXPRESSION; GENE REPRESSION; HUMAN; MICROTUBULE; NEGATIVE FEEDBACK; NEOPLASM; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TRANSCRIPTION REGULATION;

EID: 79952224367     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.11.03     Document Type: Article

References (26)

1. Weinstein IB. Addiction to oncogenes--the Achilles heal of cancer. Science 2002;297:63-4.
2. Darnell JE, Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002;2:740-9.
3. Darnell JE, Jr. STATs and gene regulation. Science 1997;277:1630-5.
4. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol 2001;13:211-7.
5. David M, Grimely PM, Finbloom DS. A nuclear tyrosine phosphatase downregulates interferon-induced gene expression. Mol Cell Biol 1993;13:5715-21.
6. Haque SJ, Flati V, Deb A, Williams BR. Roles of protein-tyrosine phosphatases in Stat1 alpha-mediated cell signaling. J Biol Chem 1995;270:25709-14.
7. Zhang X, Blenis J, Li HC, Schindler C, Chen-Kiang S. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science 1995;267:1990-4.
8. Chung J, Uchida E, Grammer TC, Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 1997;17:6508-16.
9. Hazan-Halevy I, Harris D, Liu Z, et al. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood 2010;115:2852-63.
10. Alvarez JV, Frank DA. Genome-wide analysis of STAT target genes: Elucidating the mechanism of STAT-mediated oncogenesis. Cancer Biol Ther 2004;3:1045-50.
11. Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A, Frank DA. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res 2005;65:5054-62.
12. Walker SR, Nelson EA, Zou L, Chaudhury M, et al. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res 2009;7:966-76.
13. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
14. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009;324:1713-6.
15. Germain D, Frank DA. Targeting the cytoplasmic and nuclear functions of STAT3 for cancer therapy. Clin Cancer Res 2007;13:5665-9.
16. Sano S, Itami S, Takeda K, et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 1999;18:4657-68.
17. Silver DL, Naora H, Liu J, Cheng W, Montell DJ. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 2004;64:3550-8.
18. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
19. Walker SR, Chaudhury M, Nelson EA, Frank DA. Microtubule-targeted chemotherapeutic agents Inhibit signal transducer and activator of transcription 3 (STAT3) signaling. Mol Pharmacol 2010;78:903-8.
20. Liddle FJ, Alvarez JV, Poli V, Frank DA. Tyrosine phosphorylation is required for functional activation of disulfide-containing constitutively active STAT mutants. Biochemistry 2006;45:5599-605.
21. Baylin SB. DNA methylation and gene silencing in cancer. Nature Clinical Practice Oncology 2005;2:S4-S11.
22. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;19:6613-26.
23. Frank DA. STAT inhibition in the treatment of cancer: Transcription factors as targets for molecular therapy. Curr Cancer Ther Rev 2006;2:57-65.
24. Lynch RA, Etchin J, Battle TE, Frank DA. A small-molecule enhancer of signal transducer and activator of transcription 1 transcriptional activity accentuates the antiproliferative effects of IFN-gamma in human cancer cells. Cancer Res 2007;67(3):1254-61.
25. Nelson EA, Walker SR, Kepich A, et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 2008;112:5095-102.
26. Nelson EA, Walker SR, Weisberg E, et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2010;in press.